According to a recent report by Pablo Zuanic of Zuanic & Associates, MariMed (OTC: MRMD) a multi-state cannabis operator (MSO) is positioned for significant stock gains.
The Department of Justice (DOJ) move to reclassifying cannabis from Schedule I to Schedule III provoked a noticeable uptick in cannabis market activities, as detailed in the latest industry report by Water Tower Research (WTR).
The trading volume of a stock reflects the number of shares bought and sold within a given time. This is called liquidity. The term is used because it likens the ease of converting assets to cash to the fluidity of water. Why is this…
Four lesser-valued cannabis stocks showed positive performance on Monday, defying the broader sector's downtrend. These stocks—Medical Marijuana Inc., TILT Holdings, Trees Corp., and Village Farms International —present potential…
The Department of Justice (DOJ) confirmed that it has started the formal rulemaking process to reclassify cannabis to Schedule III. This significant step reinforces the positive outlook for cannabis stocks.
Michael Berger, founder of Technical420, managing partner of StoneBridge Partners and the beloved maven behind Benzinga Cannabis Research, our cannabis stock analysis and trading subscriber-only platform, tragically passed away last…
The Department of Justice reportedly planned to issue a notice of proposed rulemaking on Thursday that would reclassify marijuana to Schedule III after a 60-day public comment period. Major players in the marijuana industry, including…
Tilray Brands is getting ready for marijuana to be reclassified as a less dangerous drug in the U.S., as the cannabis company is looking to raise money through the sale of shares so it can expand.
Shares of marijuana growers and cannabis-related companies are trading higher Thursday after President Biden announced that the Department of Justice has moved to reclassify marijuana from a Schedule I substance to a Schedule III.
Cresco Labs Inc.’s stock rose Wednesday after the U.S. cannabis-dispensary operator matched analyst estimates for first-quarter revenue, as its loss narrowed.
Wedbush Securities released a report on Curaleaf Holdings, Inc. (OTC: CURLF), the largest U.S. cannabis company by market cap, raising the stock's 12-month price target to $7.00 from $6.00 and maintaining a buy recommendation (Outperform…
Cannabis equity analysts may need to revise their 2024 earnings estimates after first-quarter results from major multi-state operators (MSOs). According to a recent report by Viridian Capital Advisors, 10 MSOs surpassed EBITDA estimates by…